Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant RSV Vaccine (CHO Cell) in Healthy Adults
NCT06642558Phase 2Active, not recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus infection (RSV) (12 arms), sponsored by MAXVAX Biotechnology. Primary endpoints: Incidence, Intensity and Causality of Adverse Events at 30 days, Incidence, Intensity and Causality of Solicited Adverse Events at 14 days and 12 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06642558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642558.